Please login to the form below

Not currently logged in
Email:
Password:

PD-L1

This page shows the latest PD-L1 news and features for those working in and with pharma, biotech and healthcare.

Breath test could predict response to immunotherapy

Breath test could predict response to immunotherapy

Although checkpoint inhibitors, including PD-1/PD-L1 blockbusters Keytruda (pembrolizumab) from MSD and Opdivo (nivolumab) from Bristol-Myers Squibb, have improved survival in various cancer areas, most patients do not ... PD-1 and PD-L1 inhibitors block

Latest news

More from news
Approximately 13 fully matching, plus 228 partially matching documents found.

Latest Intelligence

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    The presence of PD-L1 expression is often associated with a better response to anti-PD-(L) 1 therapy. ... The confounding issue is that, in the case of PD-1/PD-L1 drugs, each developer uses its own companion diagnostic that is required to prescribe the

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    cells to identify and fight cancer: the PD-1 and PD-L1 checkpoint inhibitor immunotherapies. ... PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast.

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    olaparib) plus biologic PD-L1 immunotherapy Imfinzi (durvalumab). ... patients with higher levels of PD-L1 expression in their tumours.

  • Combined immunotherapies – potential and pitfalls Combined immunotherapies – potential and pitfalls

    We hope to capitalise further on the effects of single agent anti-PD-1/PD-L1 and anti-CTLA-4 monotherapy trials and see even greater survival benefits for patients.”. ... There are a variety of strategies attempting to overcome intrinsic resistance to

  • The good, the bad and the ugly The good, the bad and the ugly

    Companies are looking to pair their PD-1/PD-L1 checkpoint inhibitors with a variety of other agents to stimulate a more robust anticancer immune response,” says Xuan.

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

  • F-star hires ex-BMS immuno-oncology leader

    Hewill oversee the clinical development of F-star’s lead product candidate, FS118, a LAG-3/PD-L1-targeting tetravalent bispecific antibody currently in aphase 1 clinical trial, recruiting the  expansion

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics